Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthmaApproval based on global phase 3 program ...

Libtayo's approval for high-risk cutaneous squamous cell carcinoma offers a new immunotherapy option, targeting PD-1 ...

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung ...

A few months after Sanofi and Regeneron’s Dupixent scored a new indication as the first and only medicine to treat eosinophilic esophagitis (EoE) in patients 12 and older, new late-stage trial data ...

Japan’s Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for ...

Dupixent For Moderate-To-Severe Asthma Treatment Market Expected To Reach ~$8.1 Billion By 2032. December 13, 2025 7:27 am - The Dupixent market for moderate-to-severe asthma is valued at $3.25 ...

RegRegon Pharmaceuticals and Sanofi recently announced that the European Commission approved Dupixent for treating moderate-to-severe chronic spontaneous urticaria in patients aged 12 and above who do ...

Dupixent is a blockbuster immunology drug that just keeps delivering for Sanofi and Regeneron, so it’s no surprise that the “franchise in a therapy” has got a new set of ads. Sanofi and Regeneron, ...

The first known lawsuit has now been filed against the makers of Dupixent (dupilumab), alleging that the popular eczema and asthma drug caused or accelerated a deadly form of lymphoma. Filed in ...

Dec 24 (Reuters) - Sanofi (SASY.PA) said on Wednesday it will buy U.S. biotech Dynavax Technologies (DVAX.O) for around $2.2 ...